Stock Screener App

無料 - Play StoreApp Store

インストールインストール

Dow:

Nasdaq:

S&P 500:

VRTX

$558.883.50%18.88

アフターアワーズ： 554.00-4.88 -0.87%

Vertex Pharmaceuticals Inc (VRTX)

Date: O: H: L: C: Vol:

Vertex Pharmaceuticals Inc (VRTX) 最新ニュース

MHRA backs expanded use of Vertex’ Casgevy - The Pharma Letter

MHRA backs expanded use of Vertex’ Casgevy - The Pharma Letter

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Quiver Quantitative

Vertex Pharmaceuticals stock hits all-time high at 560.99 USD - Investing.com

Vertex Pharmaceuticals Incorporated (VRTX) Seasonal returns chart - Yahoo Finance UK

Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga

Vertex Pharmaceuticals Incorporated (VRTX) Seasonal returns chart - Yahoo Finance Singapore

Vertex Pharmaceuticals Incorporated (VX1.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

A Return to United States ex rel. Zafirov and Vertex Pharmaceuticals - Law.com

Vertex kidney disease drug scrutinized for infection risk - STAT

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

What Would Slower New Drug Sales Do To Vertex Stock? - Trefis

Is Povetacicept The Next Chapter For Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

Vertex Pharmaceuticals (VRTX) CEO Jeff Leiden's Leadership Journ - GuruFocus

Scotiabank keeps USD 558.00 target for Vertex Pharma stock - ad-hoc-news.de

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - TradingView

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Yahoo Finance

Vertex Pharmaceuticals advances povetacicept: what it means for Vertex Pharmaceuticals stock - ad-hoc-news.de

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research

Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research

Vertex Pharmaceuticals shares may move 4.3% on earnings By Investing.com - Investing.com South Africa

The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2 - 24/7 Wall St.

Vertex Pharmaceuticals shares may move 4.3% on earnings - Investing.com

Vertex Pharmaceuticals shares may move 4.3% on earnings By Investing.com - Investing.com UK

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research

Vertex Pharma publishes kidney results as Vertex Pharma stock trades at EUR 469.45 - ad-hoc-news.de

I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move - The Motley Fool

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. - The Motley Fool

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. - The Motley Fool

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III - Yahoo Finance

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow (NASDAQ:VRTX) 2026-10-23 - Seeking Alpha

Vertex reports positive IgAN trial data, FDA decision due Nov. 30 - Investing.com Australia

Vertex Stock Looks Expensive. Does It Get Cheaper Ahead? - Trefis

Cystic Fibrosis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - StreetInsider

Vertex Pharmaceuticals Incorporated Estimates – LSE:0QZU - TradingView

Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool

Form 4 Vertex Pharmaceuticals Inc: Daniel J. Brennan (Director) For: 20 October - Investing.com UK

Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance

VERTEX PHARMACEUTICALS INC / MA Initial Statement of Beneficial Ownership - Stock Titan

Vertex Pharmaceuticals Inc. Research & Ratings | VRTX - Barron's

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool

Vertex Pharma stock at EUR 464.48 ahead of the Xetra open: biotech group - AD HOC NEWS

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

VRTXに類似

REGN$927.8913.33%

MRNA$221.720.47%

ARGX$892.870.55%

ONC$370.330.33%

RVMD$191.310.55%

GMAB$57.061.01%